Publication details
Cílená terapie a imunoterapie u chronické lymfocytární leukemie
| Title in English | Targeted therapy and immunotherapy in chronic lymphocytic leukemia |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Acta medicinae |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.actamedicinae.cz/ocasopise.htm |
| Keywords | chronic lymphocytic leukemia; targeted therapy; BTK inhibitor; Bcl-2 inhibitor; PI3K inhibitor; immunotherapy |
| Attached files | |
| Description | Summary: The treatment of chronic lymphocytic leukemia (CLL) is constantly evolving. While previously the gold standard treatment was a combination of chemotherapy and anti-CD20 monoclonal antibodies, new targeted drugs have become increasingly important in recent years, that interfere with B-cell receptor signalling or inhibit the anti-apoptotic protein Bcl-2. In contrast, hematopoietic transplantation remains indicated in the treatment of CLL in a small group of younger patients with high-risk and relapsed CLL. The efficacy of another type of cell therapy using chimeric T cells is currently being evaluated in clinical trials antigen receptor. The aim of CLL treatment is not only to stabilise the disease but also to induce a complete remission with undetectable residual disease, which can be achieved with a combination of new targeted drugs. |